Clinical Trial

Oral Tacrolimus vs Dexamethasone Micro-pulse Therapy in Pediatric Rapidly Progressing Vitiligo: A Multicenter RCT

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 19, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical study aims to compare the safety and effectiveness of two treatments-oral Tacrolimus capsules and Dexamethasone micro-pulse therapy-in children aged 4-12 years with rapidly progressing vitiligo. The study is a multicenter, randomized, controlled trial involving 90 participants, who will be divided equally into two groups. One group will receive daily Tacrolimus, while the other will take Dexamethasone on weekends. Over 24 weeks, doctors will monitor improvements in skin repigmentation, side effects, and overall health through regular check-ups and blood tests. The goal is to determine which treatment better controls disease progression and improves quality of life for children with vitiligo. Key Points: * For children with rapidly spreading vitiligo. * Compares two common medications. * Follows participants for 6 months. * Focuses on safety and effectiveness.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-23.
Status change: Not Yet Recruiting → Recruiting 2025-06-16
Trial Details
NCT Number NCT06900777
Lead Sponsor Xijing Hospital
Conditions Vitiligo, Child, Progressive Disease
Enrollment 90 participants
Start Date 2025-04-01
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-19